Project Grant R03TR005086
Award Date
3/21/24
Completion Date
2/28/25
Dollars Obligated
$159K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Austin, TX 78759, USA
Similar Awards
This is a Project Grant award from the National Eye Institute (NEI), part of the National Institutes of Health (NIH), under the Vision Research program (CFDA 93.867). The $451,000 award supports research by the University of Texas Southwestern Medical Center to investigate the role of the FIC enzyme in regulating the unfolded protein response (UPR) in the mammalian retina. Specifically, the project aims to determine if FIC-mediated modification of the BIP protein can modulate UPR activation,...
The National Eye Institute (NEI) awarded a $477,109 Project Grant (CFDA 93.867 - Vision Research) to the University of Texas Southwestern Medical Center to investigate how the PRDM13 transcriptional regulator influences retinal development and photoreceptor cell fate. The research aims to further the understanding of mammalian retinal development and mechanisms underlying healthy retinogenesis. The project period runs from May 1, 2025 to April 30, 2030. The research will explore how...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $595,566 to the University of California, Irvine to conduct research on the molecular mechanisms underlying visual disorders caused by two specific rhodopsin mutations, G90D and G90V. The research aims to establish the unique disease mechanisms of these mutations and develop therapeutic approaches for reversing their effects. Key objectives include: Comprehensive analysis of G90D and G90V...
This Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 aims to provide initial characterization of a unique mouse model developed by the awardee, Saint Louis University, to replace the entire rod G-protein beta gamma subunit complex with its cone analogue. The $151,500 grant awarded on August 1, 2024 supports this pilot proposal, which seeks to collect preliminary data for further mechanistic studies on the specificity of retinal...
This federal Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) provides $882,971 to Opus Genetics Inc. to develop a single-vector gene therapy treatment for autosomal-dominant retinitis pigmentosa (ADRP). The key products and services to be delivered include: Completion of chemistry, manufacturing, and controls (CMC) for a clinical-grade batch of the OPGX-RHO gene therapy product, including compatibility and extended stability studies....
This $110,000 Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 supports research by Greenstone Biosciences, Inc. to develop advanced drug discovery and development technologies for rare genetic disorders. The project aims to leverage induced pluripotent stem cell (iPSC) technology and artificial intelligence/machine learning (AI/ML) to accelerate and streamline the drug discovery process for myotonic dystrophy type 1 (DM1), a rare and...
This Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) provides $158,000.00 in funding to the University of California, San Diego (UCSD) to investigate the role of the GATAD1 gene in maintaining normal cardiac function and responding to cardiac stress. The research aims to elucidate the molecular mechanisms by which loss of GATAD1 leads to the development of dilated cardiomyopathy, as observed in a family with a homozygous GATAD1 mutation. The...
This Project Grant award, provided by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), focuses on assessing the in vivo efficacy, safety, and activity of an anticodon engineered transfer RNA (ACE-tRNA) in treating hereditary eye diseases caused by nonsense mutations. Specifically, the $226,135 award to the University of Iowa will evaluate the ability of the transgenic encoded ACE-tRNA-ArgUGA to rescue pigment dispersing iris disease and retinal degeneration in...
This federal Project Grant award from the Food and Drug Administration (FDA) Research program (CFDA 93.103) provides $826,251 to The Trustees of the University of Pennsylvania to perform a clinical trial evaluating gene augmentation therapy for Leber Congenital Amaurosis 5 (LCA5), a rare genetic cause of inherited retinal degeneration and vision loss. The project aims to assess the safety and efficacy of the OPGX-001 gene therapy in pediatric patients aged 13-18 years, using re-defined outcome...
The National Eye Institute (NEI) awarded a $1,490,141 Project Grant under the Vision Research program (CFDA 93.867) to the Regents of the University of Michigan to investigate photoreceptor nuclear migration defects caused by loss of the retinitis pigmentosa 2 (RP2) gene. The project aims to determine how this developmental phenotype affects photoreceptor function and health, explore methods to restore normal photoreceptor nuclear localization, and identify the ciliary signaling mechanism...